Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 10:13:659898.
doi: 10.3389/fnagi.2021.659898. eCollection 2021.

Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population

Helena Sophia Gleerup  1 , Federica Sanna  2 , Peter Høgh  3   4 , Joel Simrén  2   5 , Kaj Blennow  2   5 , Henrik Zetterberg  2   5   6   7 , Steen Gregers Hasselbalch  1   4 , Nicholas J Ashton  2   8   9   10 , Anja Hviid Simonsen  1
Affiliations

Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population

Helena Sophia Gleerup et al. Front Aging Neurosci. .

Abstract

Neurodegeneration and axonal injury result in an increasing release of neurofilament light chain (NfL) into bodily fluids, including cerebrospinal fluid (CSF) and blood. Numerous studies have shown that NfL levels in CSF and blood are increased in neurodegenerative disorders and monitor neurodegeneration. Saliva is an easily accessible biofluid that could be utilized as a biofluid measurement of Alzheimer's disease (AD) biomarkers. In this study, for the first time, salivary NfL was measured and compared to plasma NfL in a consecutive cohort of patients referred to cognitive assessments. In two mixed memory clinic cohorts, saliva samples were taken from 152 patients, AD (n = 49), mild cognitive impairment (MCI) (n = 47), non-AD (n = 56), and also 17 healthy controls. In addition, 135 also had a matching plasma sample. All saliva and plasma samples were analyzed for NfL, and the association between saliva and plasma NfL and CSF levels of total tau (t-tau), phosphorylated tau (p-tau), and beta amyloid 1-42 (Aβ42) were investigated. In total, 162/169 had quantifiable levels of salivary NfL by single molecule array (Simoa). No statistically significant differences were found in salivary NfL concentration across the diagnostic groups, but as expected, significant increases were found for plasma NfL in dementia cases (P < 0.0001). There was no association between saliva and plasma NfL levels. Furthermore, saliva NfL did not correlate with CSF Aβ42, p-tau, or tau concentrations. In conclusion, NfL is detectable in saliva but does not reflect neurodegeneration in the brain.

Keywords: Alzheimer’s disease; biomarker; dementia; neurodegeneration; neurofilament light chain; plasma; saliva.

PubMed Disclaimer

Conflict of interest statement

KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure, and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Box plots of neurofilament light chain levels in saliva and plasma and the normalized levels of saliva NfL. (A) The boxplots show the median, interquartile range, and the extreme values of salivary NfL for HC, MCI, AD, and non-AD. The 2.5–97.5 percentile of all data had been included in the boxplots. (B) The boxplots show the median, interquartile range, and the extreme values of the normalized levels of salivary NfL for HC, MCI, AD, and non-AD. The 2.5–97.5 percentile of all data had been included in the boxplots. (C) The boxplots show the median, interquartile range, and the extreme values of plasma NfL for HC, MCI, AD, and non-AD. The 2.5–97.5 percentile of all data had been included in the boxplots. NfL, neurofilament light chain; HC, healthy controls; MCI, mild cognitive impairment; AD, Alzheimer’s disease.
FIGURE 2
FIGURE 2
The association between neurofilament light chain in plasma and normalized salivary neurofilament light chain. The figure shows the relationship between NfL in plasma and normalized NfL in saliva for HC, MCI, AD, and non-AD. NIL, neurofilament light chain; HC, healthy controls; MCI, mild cognitive impairment; AD, Alzheimer’s disease.
See this image and copyright information in PMC

References

    1. Adam D. J., Milne A. A., Evans S. M., Roulston J. E., Lee A. J., Ruckley C. V., et al. (1999). Serum amylase isoenzymes in patients undergoing operation for ruptured and non-ruptured abdominal aortic aneurysm. J. Vasc. Surg. 30 229–235. 10.1016/S0741-5214(99)70132-1 - DOI - PubMed
    1. Ashton N. J., Ide M., Zetterberg H., Blennow K. (2019a). Salivary Biomarkers for Alzheimer’s Disease and Related Disorders. Neurol. Ther. 8 83–94. 10.1007/s40120-019-00168-1 - DOI - PMC - PubMed
    1. Ashton N. J., Leuzy A., Lim Y. M., Troakes C., Hortobágyi T., Höglund K., et al. (2019b). Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathol. Commun. 7:5. 10.1186/s40478-018-0649-3 - DOI - PMC - PubMed
    1. Ashton N. J., Pascoal T. A., Karikari T. K., Benedet A. L., Lantero-Rodriguez J., Brinkmalm G., et al. (2021). Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology. Acta Neuropathol. 2021:6. 10.1007/s00401-021-02275-6 - DOI - PMC - PubMed
    1. Ashton N., Janelidze S., Al Khleifat A., Leuzy A., Van Der Ende E., Karikari T., et al. (2020). Diagnostic value of plasma neurolament light: A multicentre validation study 2020. Preprint 10.21203/rs.3.rs-63386/v1 - DOI

LinkOut - more resources